Inhibition of Phosphodiesterase Type 5 by the Activator of Nitric Oxide-Sensitive Guanylyl Cyclase BAY 41-2272

Circulation

Volumn 109, Issue 14, 2004, Pages 1711-1713

  Mullershausen, Florian ^a   Russwurm, Michael ^a   Friebe, Andreas ^a   Koesling, Doris ^a,b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Inhibitors; Nitric oxide; Pharmacology; Platelets

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CYCLIC GMP; GUANYLATE CYCLASE; NITRIC OXIDE; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V; SILDENAFIL; UNCLASSIFIED DRUG;

ARTICLE; BLOOD PRESSURE REGULATION; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THROMBOCYTE AGGREGATION; VASCULAR SMOOTH MUSCLE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; CELL LINE; CYCLIC GMP; ENZYME ACTIVATION; GUANYLATE CYCLASE; HUMANS; INDAZOLES; KIDNEY; NITRIC OXIDE; NITRIC OXIDE DONORS; PHOSPHODIESTERASE INHIBITORS; PYRAZOLES; PYRIDINES; QUATERNARY AMMONIUM COMPOUNDS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECOMBINANT FUSION PROTEINS; S-NITROSOGLUTATHIONE; TRANSFECTION; VASODILATION;

EID: 5644251010     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000126286.47618.BD     Document Type: Article

References (11)

1. Rybalkin SD, Rybalkina IG, Feil R, et al. Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J Biol Chem. 2002;277:3310-3317.
2. Mullershausen F, Russwurm M, Thompson WJ, et al. Rapid nitric oxide-induced desensitization of the cGMP response is caused by increased activity of phosphodiesterase type 5 paralleled by phosphorylation of the enzyme. J Cell Biol. 2001;155:271-278.
3. Gori T, Parker JD. Nitrate tolerance: a unifying hypothesis. Circulation. 2002;106:2510-2513.
4. Ko FN, Wu CC, Kuo SC, et al. YC-1, a novel activator of platelet guanylate cyclase. Blood. 1994;84:4226-4233.
5. Wu CC, Ko FN, Kuo SC, et al. YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol. 1995;116:1973-1978.
6. Friebe A, Schultz G, Koesling D. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J. 1996;15:6863-6868.
7. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature. 2001;410:212-215.
8. Rothermund L, Friebe A, Paul M, et al. Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats. Br J Pharmacol. 2000;130:205-208.
9. Friebe A, Mullershausen F, Smolenski A, et al. YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol. 1998;54:962-967.
10. Russwurm M, Mergia E, Mullershausen F, et al. Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J Biol Chem. 2002;277:24883-24888.
11. Mullershausen F, Friebe A, Feil R, et al. Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol. 2003; 160:719-727.